Literature DB >> 22729929

Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.

Ajit C Tamhane1, Yi Wu, Cyrus R Mehta.   

Abstract

In a previous paper we studied a two-stage group sequential procedure (GSP) for testing primary and secondary endpoints where the primary endpoint serves as a gatekeeper for the secondary endpoint. We assumed a simple setup of a bivariate normal distribution for the two endpoints with the correlation coefficient ρ between them being either an unknown nuisance parameter or a known constant. Under the former assumption, we used the least favorable value of ρ = 1 to compute the critical boundaries of a conservative GSP. Under the latter assumption, we computed the critical boundaries of an exact GSP. However, neither assumption is very practical. The ρ = 1 assumption is too conservative resulting in loss of power, whereas the known ρ assumption is never true in practice. In this part I of a two-part paper on adaptive extensions of this two-stage procedure (part II deals with sample size re-estimation), we propose an intermediate approach that uses the sample correlation coefficient r from the first-stage data to adaptively adjust the secondary boundary after accounting for the sampling error in r via an upper confidence limit on ρ by using a method due to Berger and Boos. We show via simulation that this approach achieves 5-11% absolute secondary power gain for ρ ≤0.5. The preferred boundary combination in terms of high primary as well as secondary power is that of O'Brien and Fleming for the primary and of Pocock for the secondary. The proposed approach using this boundary combination achieves 72-84% relative secondary power gain (with respect to the exact GSP that assumes known ρ). We give a clinical trial example to illustrate the proposed procedure.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22729929     DOI: 10.1002/sim.5372

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

2.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

3.  Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

Authors:  Yanqiu Weng; Yuko Y Palesch; Stacia M DeSantis; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

4.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

5.  Multi-arm group sequential designs with a simultaneous stopping rule.

Authors:  S Urach; M Posch
Journal:  Stat Med       Date:  2016-08-23       Impact factor: 2.373

6.  Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.

Authors:  Thomas Jaki; Lisa V Hampson
Journal:  Stat Med       Date:  2015-10-12       Impact factor: 2.373

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.